Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

161. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease&mdash

KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease&mdash KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease—mineral and bone disorder (CKD-MBD). | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused (...) , read our . Guideline Summary NGC:011233 2017 Jul NEATS Assessment KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease—mineral and bone disorder (CKD-MBD). Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017 Jul;7

2017 National Guideline Clearinghouse (partial archive)

162. Chronic kidney disease

Chronic kidney disease Chronic kidney disease - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Chronic kidney disease Last reviewed: February 2019 Last updated: September 2018 Summary Proteinuria or haematuria, and/or a reduction in the glomerular filtration rate, for more than 3 months' duration. The most common causes are diabetes mellitus and hypertension. The majority of people are asymptomatic, and the diagnosis (...) is determined only by laboratory studies. Glycaemic control for diabetic nephropathy and optimisation of blood pressure are key in slowing the progression of disease. Increased risk for cardiovascular disease. Definition Chronic kidney disease (CKD), also known as chronic renal failure, is defined by either a pathological abnormality of the kidney, such as haematuria and/or proteinuria, or a reduction in the glomerular filtration rate to <60 mL/minute/1.73 m² for ≥3 months' duration. Kidney Disease

2017 BMJ Best Practice

163. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)

KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) - American Journal of Kidney Diseases Email/Username: Password: Remember me Search Terms Search within Search Share (...) this page Access provided by Volume 70, Issue 6, Pages 737–751 KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) x Tamara Isakova Affiliations Division of Nephrology and Hypertension, Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL

2017 National Kidney Foundation

164. Urinary Calcium Excretion and Risk of Chronic Kidney Disease in the General Population (PubMed)

Urinary Calcium Excretion and Risk of Chronic Kidney Disease in the General Population High urinary calcium excretion (UCaE) has been shown to lead to accelerated renal function decline in individuals with renal tubular diseases. It is not known whether this association also exists in the general population. Therefore, we investigated whether high UCaE is associated with risk of developing chronic kidney disease (CKD) in community-dwelling subjects.Urine samples of 5491 subjects who were free (...) of CKD at baseline and participated in the Prevention of Renal and Vascular End-Stage Disease study (a prospective, observational, general population-based cohort of Dutch men and women aged 28-75 years) were examined for UCaE. UCa concentration was measured in two 24-hour urine samples at baseline (1997-1998) by indirect potentiometry. UCaE was treated as a continuous variable and a categorical variable grouped according to sex-specific quintiles for UCaE. UCaE was compared with de novo development

Full Text available with Trip Pro

2016 Kidney international reports

165. Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity—A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial (PubMed)

Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity—A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. Recent evidence suggests that increases in both serum and intracellular magnesium (Mg) can slow or even prevent the development of vascular calcification seen in CKD. Serum calcification

Full Text available with Trip Pro

2016 Kidney international reports

166. Traditional Thermal Therapy with Indirect Moxibustion Decreases Renal Arterial Resistive Index in Patients with Chronic Kidney Disease. (PubMed)

Traditional Thermal Therapy with Indirect Moxibustion Decreases Renal Arterial Resistive Index in Patients with Chronic Kidney Disease. To evaluate the immediate effects of traditional local thermal therapy with indirect moxibustion on renal hemodynamics in patients with chronic kidney disease (CKD) by using Doppler ultrasonography (US).Examiner-blinded crossover study.Forty-three participants with CKD (mean age ± standard deviation [SD], 44 ± 15 years; estimated glomerular filtration rate

2016 Journal of alternative and complementary medicine (New York, N.Y.)

167. Chronic Kidney Disease. (PubMed)

Chronic Kidney Disease. The definition and classification of chronic kidney disease (CKD) have evolved over time, but current international guidelines define this condition as decreased kidney function shown by glomerular filtration rate (GFR) of less than 60 mL/min per 1·73 m2, or markers of kidney damage, or both, of at least 3 months duration, regardless of the underlying cause. Diabetes and hypertension are the main causes of CKD in all high-income and middle-income countries, and also (...) is measured either via exogenous markers (eg, DTPA, iohexol), or estimated using equations. Presence of proteinuria is associated with increased risk of progression of CKD and death. Kidney biopsy samples can show definitive evidence of CKD, through common changes such as glomerular sclerosis, tubular atrophy, and interstitial fibrosis. Complications include anaemia due to reduced production of erythropoietin by the kidney; reduced red blood cell survival and iron deficiency; and mineral bone disease

2016 Lancet

168. Metabolically Healthy Obesity and Development of Chronic Kidney Disease (PubMed)

Metabolically Healthy Obesity and Development of Chronic Kidney Disease 27842407 2017 12 07 2018 12 02 1539-3704 165 10 2016 11 15 Annals of internal medicine Ann. Intern. Med. Metabolically Healthy Obesity and Development of Chronic Kidney Disease. 743 10.7326/L16-0407 Kahn Henry S HS From Centers for Disease Control and Prevention, Atlanta, Georgia. Pavkov Meda E ME From Centers for Disease Control and Prevention, Atlanta, Georgia. eng CC999999 Intramural CDC HHS United States Journal Article (...) Comment United States Ann Intern Med 0372351 0003-4819 AIM IM Ann Intern Med. 2016 Mar 1;164(5):305-12 26857595 Ann Intern Med. 2016 Nov 15;165(10 ):744-745 27842405 Body Mass Index Humans Obesity Obesity, Metabolically Benign Renal Insufficiency, Chronic 2016 11 15 6 0 2016 11 15 6 0 2017 12 8 6 0 ppublish 27842407 2582915 10.7326/L16-0407 PMC5308792 NIHMS848359 Int J Obes (Lond). 2016 May;40(5):883-6 26841729 PLoS One. 2016 Jan 05;11(1):e0146057 26731527 Ann Intern Med. 2016 Mar 1;164(5):305-12

Full Text available with Trip Pro

2016 Annals of Internal Medicine

169. Interventions for chronic kidney disease-associated restless legs syndrome. (PubMed)

Interventions for chronic kidney disease-associated restless legs syndrome. Restless legs syndrome (RLS) is defined as the spontaneous movement of the limbs (mainly legs) associated with unpleasant, sometimes painful sensation which is relieved by moving the affected limb. Prevalence of RLS among people on dialysis has been estimated between 6.6% and 80%. RLS symptoms contribute to impaired quality of life and people with RLS are shown to have increased cardiovascular morbidity (...) and mortality.Various pharmacological and non-pharmacological interventions have been used to treat primary RLS. However, the evidence for use of these interventions in people with chronic kidney disease (CKD) is not well established. The agents used in the treatment of primary RLS may be limited by the side effects in people with CKD due to increased comorbidity and altered drug pharmacokinetics.The aim of this review was to critically look at the benefits, efficacy and safety of various treatment options used

Full Text available with Trip Pro

2016 Cochrane

170. Sarcopenia, Obesity, and Mortality in US Adults With and Without Chronic Kidney Disease (PubMed)

Sarcopenia, Obesity, and Mortality in US Adults With and Without Chronic Kidney Disease In pre-dialysis chronic kidney disease (CKD), the association of muscle mass with mortality is poorly defined, and no study has examined outcomes related to the co-occurrence of low muscle mass and excess adiposity (sarcopenic-obesity). Methods: We examined abnormalities of muscle and fat mass in adult participants of the National Health and Nutrition Examination Survey 1999-2004. We determined whether

Full Text available with Trip Pro

2016 Kidney international reports

171. Downregulation of AdipoR1 is Associated with increased Circulating Adiponectin Levels in Serbian Chronic Kidney Disease Patients (PubMed)

Downregulation of AdipoR1 is Associated with increased Circulating Adiponectin Levels in Serbian Chronic Kidney Disease Patients Since the rise in plasma adiponectin levels in chronic kidney disease (CKD) patients has not yet been elucidated, we sought to investigate if patients on hemodialysis (HD) have altered expression of adiponectin receptors in peripheral blood mononuclear cells (PBMCs) compared to healthy subjects.This study included 31 patients with chronic kidney disease on HD and 33

Full Text available with Trip Pro

2016 Journal of medical biochemistry

172. Hypertension Control, Apparent Treatment Resistance, and Outcomes in the Elderly Population With Chronic Kidney Disease (PubMed)

Hypertension Control, Apparent Treatment Resistance, and Outcomes in the Elderly Population With Chronic Kidney Disease Chronic kidney disease (CKD) is often associated with poor hypertension control and treatment resistance, but whether CKD modifies the effect of hypertension control on outcomes is unknown.We studied 10-year mortality and cardiovascular events according to hypertension control status and CKD (glomerular filtration rate <60 ml/min/1.73m2) in 4262 community-dwelling individuals

Full Text available with Trip Pro

2016 Kidney international reports

173. Tackling the Fallout From Chronic Kidney Disease of Unknown Etiology: Why We Need to Focus on Providing Peritoneal Dialysis in Rural, Low-Resource Settings (PubMed)

Tackling the Fallout From Chronic Kidney Disease of Unknown Etiology: Why We Need to Focus on Providing Peritoneal Dialysis in Rural, Low-Resource Settings 29142936 2018 11 13 2468-0249 2 1 2017 Jan Kidney international reports Kidney Int Rep Tackling the Fallout From Chronic Kidney Disease of Unknown Etiology: Why We Need to Focus on Providing Peritoneal Dialysis in Rural, Low-Resource Settings. 1-4 10.1016/j.ekir.2016.10.004 Nanayakkara Nishanthe N Department of Medicine, Teaching Hospital (...) A Department of Medicine, Division of Nephrology, Stanford University School of Medicine, Palo Alto, California, USA. Department of Medicine, Division of Nephrology, Santa Clara Valley Medical Center, San Jose, California, USA. Anand Shuchi S Department of Medicine, Division of Nephrology, Stanford University School of Medicine, Palo Alto, California, USA. eng K23 DK101826 DK NIDDK NIH HHS United States Editorial 2016 10 26 United States Kidney Int Rep 101684752 2468-0249 2017 11 17 6 0 2017 11 17 6 0 2017

Full Text available with Trip Pro

2016 Kidney international reports

174. Timely Referral to Outpatient Nephrology Care Slows Progression and Reduces Treatment Costs of Chronic Kidney Diseases (PubMed)

Timely Referral to Outpatient Nephrology Care Slows Progression and Reduces Treatment Costs of Chronic Kidney Diseases We present a new approach to evaluate the importance of ambulatory nephrology care in patients with chronic kidney disease (CKD).An anonymized health claims database of German insurance companies was searched in a retrospective analysis for patients with CKD using the codes of the International Classification of Diseases, 10th German modification. A total of 105,219 patients (...) with CKD were identified. Patients were assigned to the group "timely referral," when nephrology care was present in the starting year 2009, or initiated during the following 3 years in CKD1-4. Using frequency matching for age and gender, 21,024 of the late referral group were matched with the equal number of patients in the timely referral group. Hospital admission rates, total treatment costs, and kidney function (change in CKD stages, start of dialysis, mortality) were documented each year during

Full Text available with Trip Pro

2016 Kidney international reports

175. Interventions for chronic kidney disease in people with sickle cell disease. (PubMed)

Interventions for chronic kidney disease in people with sickle cell disease. This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the effectiveness of any intervention in preventing or reducing kidney complications or CKD in people with SCD (including red blood cell transfusions, hydroxyurea and ACEI (either alone or in combination with each other)).

Full Text available with Trip Pro

2016 Cochrane

176. The Green Tea Polyphenol(—)-epigallocatechin-3-gallate and its beneficial roles in chronic kidney disease (PubMed)

The Green Tea Polyphenol(—)-epigallocatechin-3-gallate and its beneficial roles in chronic kidney disease Chronic kidney disease (CKD), a condition that affects around 10% of the population, has become a significant public health concern. Current therapeutic strategies to slow down the progression of CKD remain limited. Thus, it is urgent to develop new strategies to manage the patients with CKD. Work within the past decade has improved our understanding of the mechanisms contributing to CKD (...) . In particular, oxidative stress as well as inflammation appears to play a pivotal role in CKD progression. ()-Epigallocatechin-3-gallate (EGCG), the major catechin of green tea extract, is known as a powerful antioxidant and reactive oxygen species scavenger. Various studies have shown EGCG has a potential role in chronic kidney disease models. It is suggested that EGCG modulates cellular and molecular mechanisms via inflammation-related NF-кB and Nrf2 signaling pathway, as well as apoptosis-related ER

Full Text available with Trip Pro

2016 Journal of translational internal medicine

177. Sevelamer for the Treatment of Patients with Chronic Kidney Disease: A Review of Clinical and Cost-Effectiveness

Sevelamer for the Treatment of Patients with Chronic Kidney Disease: A Review of Clinical and Cost-Effectiveness Sevelamer for the Treatment of Patients with Chronic Kidney Disease: A Review of Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Sevelamer for the Treatment of Patients with Chronic Kidney Disease: A Review of Clinical and Cost-Effectiveness Sevelamer for the Treatment of Patients with Chronic Kidney Disease: A Review of Clinical and Cost-Effectiveness (...) Published on: September 21, 2016 Project Number: RC0810-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of sevelamer for the treatment of patients with chronic kidney disease? What is the cost-effectiveness of sevelamer for the treatment of patients with chronic kidney disease? Key Message Overall, the evidence suggests that sevelamer is more effective at reducing serum calcium levels and lowering

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

178. Depression in Chronic Kidney Disease and End-Stage Renal Disease: Similarities and Differences in Diagnosis, Epidemiology, and Management (PubMed)

Depression in Chronic Kidney Disease and End-Stage Renal Disease: Similarities and Differences in Diagnosis, Epidemiology, and Management Depression is highly prevalent and is associated with poor quality of life and increased mortality among adults with chronic kidney disease (CKD), including those with end-stage renal disease (ESRD). However, there are several important differences in the diagnosis, epidemiology, and management of depression between patients with non-dialysis-dependent CKD

Full Text available with Trip Pro

2016 Kidney international reports

179. Evaluation of Renal Blood Flow in Chronic Kidney Disease Using Arterial Spin Labeling Perfusion Magnetic Resonance Imaging (PubMed)

Evaluation of Renal Blood Flow in Chronic Kidney Disease Using Arterial Spin Labeling Perfusion Magnetic Resonance Imaging Chronic kidney disease (CKD) is known to be associated with reduced renal blood flow. However, data to-date in humans is limited.In this study, non-invasive arterial spin labeling (ASL) MRI data was acquired in 33 patients with diabetes and stage-3 CKD, and 30 healthy controls.A significantly lower renal blood flow both in cortex (108.4±36.4 vs. 207.3±41.8; p<0.001, d=2.52

Full Text available with Trip Pro

2016 Kidney international reports

180. Iron (III) isomaltoside 1000 (Diafer) - iron deficiency in adults with chronic kidney disease (CKD) on dialysis

Iron (III) isomaltoside 1000 (Diafer) - iron deficiency in adults with chronic kidney disease (CKD) on dialysis 1 Published 13 February 2017 Re-submission iron III isomaltoside 1000 (contains 50mg iron per mL) (Diafer ® ), solution for injection SMC No. (1177/16) Pharmacosmos UK Limited 13 January 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in Scotland (...) . The advice is summarised as follows: ADVICE: following a resubmission iron III isomaltoside 1000 5% (Diafer ® ) is accepted for use within NHS Scotland. Indication under review: For the treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis, when oral iron preparations are ineffective or cannot be used. Iron III isomaltoside 1000 at a higher (10%) concentration has been shown to be non-inferior to another intravenous iron product in maintaining haemoglobin concentration

2016 Scottish Medicines Consortium